One-Year Outcomes of Femoropopliteal Chronic Total Occlusions Treated With Percutaneous Provisional Approach: A Single Center Experience (Percutaneous Treatment of Femoropopliteal CTO)

Objective: The aim of the present study was to evaluate the results of percutaneous treated femoropopliteal chronic total occlu-sions (CTOs).Methods: A total of 204 limbs (167 patients) that were treated with drug-coated balloon angioplasty and/or self-expandable stent implantation between January 2015 and December 2017 were assessed. Immediate and follow-up features were expressed with frequency tables, and Kaplan–Meier analysis was calculated for primary, primary-assisted, and secondary patency rates.Results: In 202 (99%) cases, optimal targeted success was achieved. Death, arterial rupture requiring surgery, and myocardial in-farction were not observed in the hospital period. In only 6 (3%) cases, an entry site hematoma developed but recovered without any intervention. Restenosis in 22 patients (5 in the first 6 months and 17 in the second 6 months) and reocclusion in 8 patients (2 in the first 6 months and 6 in the second 6 months) were observed in a 1-year follow-up. Primary, primary-assisted, and secondary patency rates were found to be 85.1%, 96%, and 98%, respectively, at the end of the first year.Conclusion: Percutaneous revascularization of femoropopliteal CTOs appears to be safe and effective.

PDF

___

1. Weinberg MD, Lau JF, Rosenfield K, Olin JW. Peripheral artery dis-ease. Part 2: medical and endovascular treatment. Nat Rev Cardiol 2011; 8: 429-41. [CrossRef ]
2. Hobbs S, Bradbury A. Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur J Vasc Endovasc Surg 2003; 26: 341-7. [CrossRef ]
3. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. Annu Rev Med 2005; 56: 249-72. [CrossRef ]
4. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collabo-ration with the European Society for Vascular Surgery (ESVS): Doc-ument covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEn-dorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-816. [CrossRef ]
5. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011; 54: 1042-50. [CrossRef ]
6. Schönefeld E, Schönefeld T, Osada N, Austermann M, Torsello G. Long stents for long femoropopliteal lesions–first results of 128 Pro-tege stents. Zentralbl Chir 2009; 134: 310. [CrossRef ]
7. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation 2016; 133: 1472-83. [CrossRef ]
8. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremi-ty ischemia: revised version. J Vasc Surg 1997; 26: 517-38.[CrossRef ]
9. Baril DT, Chaer RA, Rhee RY, Makaroun MS, Marone LK. Endovascular interventions for TASC II D femoropopliteal lesions. J Vasc Surg 2010; 51: 1406-12. [CrossRef ]
10. Yin MY, Jiang ME, Huang XT, Lu M, Lu XW, Huang Y, et al. Endovascu-lar interventions for TransAtlantic InterSociety Consensus II C and D femoropopliteal lesions. Chin Med J (Engl) 2013; 126: 415-20.
11. Wong G, Lahsaei S, Aoun J, Garcia LA. Management of common femoral artery occlusive disease: A review of endovascular treat-ment strategies and outcomes. Catheter Cardiovasc Interv 2019; 93: 514-21.[CrossRef ]
12. Bhatt H, Janzer S, George JC. Crossing techniques and devices in femoropopliteal chronic total occlusion intervention. Cardiovasc Revasc Med 2017; 18: 623-31. [CrossRef ]
13. Lichtenberg M, Breuckmann F, Kramer V, Betge S, Sixt S, Hailer B, et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopli-teal lesions - the BIOFLEX PEACE All-Comers Registry. Vasa 2019; 48: 425-432. [CrossRef ]
14. Dayama A, Tsilimparis N, Kolakowski S, Matolo NM, Humphries MD. Clinical outcomes of bypass-first versus endovascular-first strategy in patients with chronic limb-threatening ischemia due to infra-geniculate arterial disease. J Vasc Surg 2019; 69: 156-63. [CrossRef ]
15. Okuno S, Iida O, Iida T, Takahara M, Yamaoka T, Kitano I, et al. Com-parison of clinical outcomes between endovascular therapy with self-expandable nitinol stent and femoral-popliteal bypass for trans-atlantic ınter-society consensus II C and D femoropopliteal lesions. Ann Vasc Surg 2019; 57: 137-43. [CrossRef ]
16. Xu Y, Jia X, Zhang J, Zhuang B, Fu W, Wu D, et al. Drug-coated bal-loon angioplasty compared with uncoated balloons in the treat-ment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of acoart I. JACC Cardiovasc Interv 2018; 11: 2347-53. [CrossRef ]
17. Scheinert D, Micari A, Brodmann M, Tepe G, Peeters P, Jaff MR, et al. Drug-Coated Balloon Treatment for Femoropopliteal Artery Dis-ease. Circ Cardiovasc Interv 2018; 11: e005654. [CrossRef ]
18. Surowiec SM, Davies MG, Eberly SW, Rhodes JM, Illig KA, Shortell CK, et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg 2005; 41: 269-78.[CrossRef ]
19. Acin F, de Haro J, Bleda S, Varela C, Esparza L. Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of random-ized controlled trials. J Endovasc Ther 2012; 19: 585-95. [CrossRef ]
20. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7: e011245. [CrossRef ]
21. Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Car-diol 2019; 73: 2550-63. [CrossRef